<p>Merus N.V.（纳斯达克代码：MRUS - 获取免费报告）主要股东 A/S Genmab 于 12 月 18 日（星期四）交易中收购了 212,177 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总价值为 20,581,169.00 美元。交易后，该内部人士在公司持有 71,946,801 股，估计价值约为 6,978,839,697 美元。这代表其持股比例增加了 0.30%。此次收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。持有公司 10% 或以上股份的主要股东需向 SEC 披露其买卖情况。</p>
<p>A/S Genmab 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 19 日（星期五），A/S Genmab 购买了 66,264 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总交易额为 6,427,608.00 美元。</li>
<li>在 12 月 17 日（星期三），A/S Genmab 购买了 150,795 股 Merus 股票。这些股票的平均成本为每股 97.00 美元，总价值为 14,627,115.00 美元。</li>
<li>在 12 月 16 日（星期二），A/S Genmab 购买了 120,752 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总价值为 11,712,944.00 美元。</li>
</ul>
<h2>Merus 股票下跌 0.1%</h2>
<p>在周一的午盘交易中，Merus 股票下跌 0.06 美元，报 96.95 美元。该公司的股票交易量为 501,154 股，而其平均交易量为 1,271,123 股。该股票的市值为 73.5 亿美元，市盈率为-18.29，贝塔值为 1.06。Merus N.V.的十二个月最低价为 33.19 美元，最高价为 97.14 美元。该股票的 50 日移动平均价格为 95.66 美元，200 日移动平均价格为 76.05 美元。</p>
<h2>分析师设定新目标价</h2>
<p>多家券商对 MRUS 进行了评估。Lifesci Capital 在 9 月 30 日（星期二）的研究报告中重申了对 Merus 的 “市场表现” 评级，并设定了 97.00 美元的目标价。巴克莱在 9 月 30 日（星期二）的研究报告中重申了 “持平” 评级，并将 Merus 的目标价下调至 97.00 美元（之前为 112.00 美元）。Leerink Partners 在 10 月 5 日（星期日）的研究报告中将 Merus 的评级从 “强力买入” 下调至 “持有”。工业联盟证券在 8 月 25 日（星期一）的一份研究报告中设定了 Merus 的目标价为 90.00 美元。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Merus 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，十四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Merus 目前的平均评级为 “持有”，平均目标价为 93.56 美元。</p>
<p><strong>查看我们对 MRUS 的最新分析</strong></p>
<h2>Merus 的机构交易</h2>
<p>机构投资者最近买卖了该公司的股票。Avoro Capital Advisors LLC 在第三季度将其在 Merus 的持股增加了 12.3%。Avoro Capital Advisors LLC 目前持有 3,542,500 股生物技术公司的股票，价值 333,526,000 美元，此前在上个季度增持了 386,945 股。Paradigm Biocapital Advisors LP 在第一季度将其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 目前持有 3,369,699 股生物技术公司的股票，价值 141,831,000 美元，此前在上个季度增持了 1,679,777 股。Holocene Advisors LP 在第二季度将其在 Merus 的持股增加了 18.8%。Holocene Advisors LP 目前持有 2,225,241 股生物技术公司的股票，价值 117,048,000 美元，此前在上个季度增持了 351,616 股。Westfield Capital Management Co. LP 在第三季度将其在 Merus 的持股增加了 4.4%。Westfield Capital Management Co. LP 目前持有 2,132,489 股生物技术公司的股票，价值 200,774,000 美元，此前在上个季度增持了 90,101 股。最后，Woodline Partners LP 在第三季度将其在 Merus 的持股增加了 8.5%。Woodline Partners LP 目前持有 1,674,167 股生物技术公司的股票，价值 157,623,000 美元，此前在此期间增持了 131,267 股。机构投资者持有该公司 96.14% 的股份。</p>
<h2>关于 Merus</h2>
<p>（获取免费报告）</p>
<p>Merus NV 是一家临床阶段的免疫肿瘤学公司，专注于双特异性抗体治疗药物的发现和开发，以治疗癌症。利用其专有的 Biclonics®平台，Merus 设计了能够同时与免疫细胞和肿瘤靶点结合的全人源双特异性抗体。该公司的研究工作旨在创造具有优化效力、选择性和安全性特征的新疗法。</p>
<p>Merus 的研发管线涵盖多个处于临床前和临床开发不同阶段的 Biclonics 候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>黄金警报</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUX9TeW1ib2w9TVJVUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Merus 吗？</h2>
<p>在你考虑 Merus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Merus 并不在名单上。</p>
<p>虽然 Merus 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRUS

GMAB

<p>A/S Genmab 以每股 97 美元的价格收购了 212,177 股 Merus N.V.的股票，总计 2058 万美元，增持幅度为 0.30%。该交易已向 SEC 披露。Merus 的股票目前交易价格为 96.95 美元，市值为 73.5 亿美元。分析师对 Merus 的评级不一，平均目标价为 93.56 美元。机构投资者积极交易 Merus 股票，Avoro Capital Advisors LLC 等公司的持股显著增加</p>

<p>Merus N.V. (NASDAQ:MRUS - Get Free Report) major shareholder A/S Genmab acquired 212,177 shares of Merus stock in a transaction dated Thursday, December 18th. The shares were acquired at an average price of $97.00 per share, with a total value of $20,581,169.00. Following the transaction, the insider owned 71,946,801 shares in the company, valued at approximately $6,978,839,697. This represents a 0.30% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.</p>
<div class="lb-trans"><p>Merus N.V.（纳斯达克代码：MRUS - 获取免费报告）主要股东 A/S Genmab 于 12 月 18 日（星期四）交易中收购了 212,177 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总价值为 20,581,169.00 美元。交易后，该内部人士在公司持有 71,946,801 股，估计价值约为 6,978,839,697 美元。这代表其持股比例增加了 0.30%。此次收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。持有公司 10% 或以上股份的主要股东需向 SEC 披露其买卖情况。</p>
</div><p>A/S Genmab also recently made the following trade(s):</p>
<div class="lb-trans"><p>A/S Genmab 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, December 19th, A/S Genmab bought 66,264 shares of Merus stock. The stock was acquired at an average price of $97.00 per share, for a total transaction of $6,427,608.00.</li>
<li>On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The shares were acquired at an average cost of $97.00 per share, with a total value of $14,627,115.00.</li>
<li>On Tuesday, December 16th, A/S Genmab bought 120,752 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, with a total value of $11,712,944.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 19 日（星期五），A/S Genmab 购买了 66,264 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总交易额为 6,427,608.00 美元。</li>
<li>在 12 月 17 日（星期三），A/S Genmab 购买了 150,795 股 Merus 股票。这些股票的平均成本为每股 97.00 美元，总价值为 14,627,115.00 美元。</li>
<li>在 12 月 16 日（星期二），A/S Genmab 购买了 120,752 股 Merus 股票。这些股票的平均收购价格为每股 97.00 美元，总价值为 11,712,944.00 美元。</li>
</ul>
</div><h2>Merus Stock Down 0.1%</h2>
<div class="lb-trans"><h2>Merus 股票下跌 0.1%</h2>
</div><p>Merus stock traded down $0.06 during mid-day trading on Monday, hitting $96.95. The company's stock had a trading volume of 501,154 shares, compared to its average volume of 1,271,123. The stock has a market capitalization of $7.35 billion, a P/E ratio of -18.29 and a beta of 1.06. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $97.14. The stock's fifty day moving average price is $95.66 and its two-hundred day moving average price is $76.05.</p>
<div class="lb-trans"><p>在周一的午盘交易中，Merus 股票下跌 0.06 美元，报 96.95 美元。该公司的股票交易量为 501,154 股，而其平均交易量为 1,271,123 股。该股票的市值为 73.5 亿美元，市盈率为-18.29，贝塔值为 1.06。Merus N.V.的十二个月最低价为 33.19 美元，最高价为 97.14 美元。该股票的 50 日移动平均价格为 95.66 美元，200 日移动平均价格为 76.05 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of brokerages have weighed in on MRUS. Lifesci Capital reaffirmed a &#34;market perform&#34; rating and issued a $97.00 price target on shares of Merus in a research report on Tuesday, September 30th. Barclays reiterated an &#34;equal weight&#34; rating and issued a $97.00 price objective (down previously from $112.00) on shares of Merus in a research report on Tuesday, September 30th. Leerink Partnrs downgraded shares of Merus from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, October 5th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a research note on Monday, August 25th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Merus in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merus currently has an average rating of &#34;Hold&#34; and an average price target of $93.56.</p>
<div class="lb-trans"><p>多家券商对 MRUS 进行了评估。Lifesci Capital 在 9 月 30 日（星期二）的研究报告中重申了对 Merus 的 “市场表现” 评级，并设定了 97.00 美元的目标价。巴克莱在 9 月 30 日（星期二）的研究报告中重申了 “持平” 评级，并将 Merus 的目标价下调至 97.00 美元（之前为 112.00 美元）。Leerink Partners 在 10 月 5 日（星期日）的研究报告中将 Merus 的评级从 “强力买入” 下调至 “持有”。工业联盟证券在 8 月 25 日（星期一）的一份研究报告中设定了 Merus 的目标价为 90.00 美元。最后，Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Merus 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，十四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，Merus 目前的平均评级为 “持有”，平均目标价为 93.56 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on MRUS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MRUS 的最新分析</strong></p>
</div><h2>Institutional Trading of Merus</h2>
<div class="lb-trans"><h2>Merus 的机构交易</h2>
</div><p>Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC grew its position in Merus by 12.3% during the 3rd quarter. Avoro Capital Advisors LLC now owns 3,542,500 shares of the biotechnology company's stock worth $333,526,000 after acquiring an additional 386,945 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% in the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after acquiring an additional 1,679,777 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Merus by 18.8% in the second quarter. Holocene Advisors LP now owns 2,225,241 shares of the biotechnology company's stock valued at $117,048,000 after buying an additional 351,616 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Merus by 4.4% in the third quarter. Westfield Capital Management Co. LP now owns 2,132,489 shares of the biotechnology company's stock valued at $200,774,000 after purchasing an additional 90,101 shares during the last quarter. Finally, Woodline Partners LP grew its stake in Merus by 8.5% in the 3rd quarter. Woodline Partners LP now owns 1,674,167 shares of the biotechnology company's stock valued at $157,623,000 after purchasing an additional 131,267 shares during the period. Institutional investors own 96.14% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买卖了该公司的股票。Avoro Capital Advisors LLC 在第三季度将其在 Merus 的持股增加了 12.3%。Avoro Capital Advisors LLC 目前持有 3,542,500 股生物技术公司的股票，价值 333,526,000 美元，此前在上个季度增持了 386,945 股。Paradigm Biocapital Advisors LP 在第一季度将其在 Merus 的持股增加了 99.4%。Paradigm Biocapital Advisors LP 目前持有 3,369,699 股生物技术公司的股票，价值 141,831,000 美元，此前在上个季度增持了 1,679,777 股。Holocene Advisors LP 在第二季度将其在 Merus 的持股增加了 18.8%。Holocene Advisors LP 目前持有 2,225,241 股生物技术公司的股票，价值 117,048,000 美元，此前在上个季度增持了 351,616 股。Westfield Capital Management Co. LP 在第三季度将其在 Merus 的持股增加了 4.4%。Westfield Capital Management Co. LP 目前持有 2,132,489 股生物技术公司的股票，价值 200,774,000 美元，此前在上个季度增持了 90,101 股。最后，Woodline Partners LP 在第三季度将其在 Merus 的持股增加了 8.5%。Woodline Partners LP 目前持有 1,674,167 股生物技术公司的股票，价值 157,623,000 美元，此前在此期间增持了 131,267 股。机构投资者持有该公司 96.14% 的股份。</p>
</div><h2>About Merus</h2>
<div class="lb-trans"><h2>关于 Merus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company's research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.</p>
<div class="lb-trans"><p>Merus NV 是一家临床阶段的免疫肿瘤学公司，专注于双特异性抗体治疗药物的发现和开发，以治疗癌症。利用其专有的 Biclonics®平台，Merus 设计了能够同时与免疫细胞和肿瘤靶点结合的全人源双特异性抗体。该公司的研究工作旨在创造具有优化效力、选择性和安全性特征的新疗法。</p>
</div><p>The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>Merus 的研发管线涵盖多个处于临床前和临床开发不同阶段的 Biclonics 候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>GOLD ALERT</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>华尔街股票挑选者评选 2026 年第一股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>黄金警报</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Merus 吗？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Merus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Merus 并不在名单上。</p>
</div><p>While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Genmab A/S 收购了 212,177 股 Merus（NASDAQ:MRUS）的股票